The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Unicorn Fund
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Unicorn Fund, a non-promoter entity, has acquired 4,78,000 shares (6.6022%) of Accretion Nutraveda Ltd listed on BSE. Before this acquisition, Unicorn Fund held NIL shares in the company. The bulk of the acquisition (4,71,000 shares) came through the company's IPO — 4,66,000 shares as an Anchor investor and 5,000 shares as a QIB Ex-Anchor on February 4, 2026. An additional 7,000 shares were bought from the secondary market on February 4-5, 2026. This disclosure is filed under SEBI's SAST Regulation 29(1) because the acquirer's holding crossed the 5% threshold, triggering mandatory reporting.
Institutional participation of over 6.6% via the IPO signals strong anchor and QIB demand at listing, which is generally positive for stock credibility. Shareholders should note that as a non-promoter, Unicorn Fund can continue creeping acquisitions up to 10% without further open offer obligations under SEBI takeover rules.